| Literature DB >> 31462966 |
Inge Groenendijk1, Laura den Boeft1, Luc J C van Loon2, Lisette C P G M de Groot1.
Abstract
Protein may play a beneficial role in the prevention of bone loss and in slowing down osteoporosis. The effect of dietary protein may be different in older adults compared to younger adults, since this population has a greater need for protein. The aim of this systematic review and meta-analysis was to investigate the impact of a dietary protein intake above the Recommended Dietary Allowance (RDA) of 0.8 g/kg body weight/day from any source on Bone Mineral Density (BMD)/Bone Mineral Content (BMC), bone turnover markers, and fracture risk in older adults compared to a lower dietary protein intake. A systematic search was conducted through October 2018 in 3 databases: CENTRAL, MEDLINE, and EMBASE. We included all prospective cohort studies and Randomized Controlled Trials (RCTs) among adults aged ≥65 years that examined the relation between protein intake on bone health outcomes. Two investigators independently conducted abstract and full-text screenings, data extractions, and risk of bias assessments. Authors were contacted for missing data. After screening of 523 records, twelve cohort studies and one RCT were included. Qualitative evaluation showed a positive trend between higher protein intakes and higher femoral neck and total hip BMD. Meta-analysis of four cohort studies showed that higher protein intakes resulted in a significant decrease in hip fractures (pooled hazard ratio: 0.89; 95% confidence interval: 0.84, 0.94). This systematic review supports that a protein intake above the current RDA may reduce hip fracture risk and may play a beneficial role in BMD maintenance and loss in older adults.Entities:
Keywords: Bone; Bone density; Fractures; Older adults; Protein
Year: 2019 PMID: 31462966 PMCID: PMC6704341 DOI: 10.1016/j.csbj.2019.07.005
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Bone health outcomes of interest.
| Outcome | Sites or markers |
|---|---|
| BMC | Total body |
| BMD | Total body, total hip, femoral neck, lumbar spine |
| Bone turnover markers | Alkaline phosphatase, bone alkaline phosphatase, bone-specific alkaline phosphatase, collagen type I cross-linked C-terminal telopeptide, collagen type I cross-linked N-terminal telopeptide, C-terminal type 1 procollagen, N-terminal type 1 procollegen, deoxypyridinoline, hydroxyproline, pyridinoline, osteocalcin |
| Fracture | All sites |
Note. BMC = Bone Mineral Content; BMD = Bone Mineral Density.
Fig. 1Flow diagram of study selection.
Summary table of cohort studies included in the analysis.
| First author, year [ref] | Cohort name (country) | Participants | N baseline/ analysed | Baseline mean age(SD) or age range (y) | Exposure assessment | Mean protein intake | Follow-up (y) | Relevant outcomes | Effect sizes |
|---|---|---|---|---|---|---|---|---|---|
| Beasley, 2014 [ | Women's Health Initiative (US) | Post- menopausal women | 161,808/ 144,580 (whole sample) | 55–79; subgroups: 65 & 75 | FFQ + calibrated with biomarkers | 0.52, 0.75, 0.92, 1.11, 1.50 (quantiles, whole sample) | 6 | TB BMD | Per 20% increase in protein intake: 65 y: mean 0.003 (0.001, 0.005) ns |
| Hip BMD | 65 y: mean 0.003 (0.001, 0.005) ns 75 y: mean 0.004 (0.001, 0.007) ns | ||||||||
| Any fracture | 65 y: HR 0.99 (0.96, 1.01) ns 75 y: HR 0.96 (0.91, 1.02) ns | ||||||||
| Hip fracture | 65 y: HR 0.91 (0.82, 0.99) ns | ||||||||
| Cauley, 2016 [ | Osteoporotic Fractures in Men Study (US) | Men >65 y | 5994/5876 | No fracture: 73.5(5.8); fracture: 77.8(6.1) | Block semi-quantitative FFQ | No fracture: 16.1%; fracture: 15.3% of EI | 8.6 | Hip fracture | Per SD increase in protein intake (2.9% of EI): |
| Chan, 2011 [ | - (China) | Men and women ≥65 y | 2944/2217 (1225 men, 992 women) | Men: 71.6(4.6); women: 72.0(5.1) | FFQ | Men 88.8, women 65.7 g/d. | 4 | Per unit increase in energy-adjusted protein intake: | |
| Hip BMD | Men: B -0.007 SE 0.005 p 0.147 | ||||||||
| FN BMD | Men: B -0.013 SE 0.008 p 0.088 | ||||||||
| Dawson-Hughes, 2002 [ | - (US) | Men and women ≥65 y | 389/342 | Supplemented group: 70(5), 71(4), 70(4); placebo group: 71(5), 71(5), 71(5) (tertiles) | Willett semi-quantitative FFQ | 9.6–15.5, 15.5–18.2, 18.2–29.1% of EI (tertiles). Supplemented: 0.96, 1.07, 1.17; placebo: 0.90, 1.08, 1.20 g/kg bw/d (estimated values) | 3 | Supplemented group protein T3 vs T1: | |
| TB BMD | NR, less loss/gain p 0.042 | ||||||||
| FN BMD | NR, less loss/gain p 0.011 | ||||||||
| Spine BMD | NR, no difference ns | ||||||||
| Osteocalcin | NR, no difference ns | ||||||||
| NR, no difference ns | |||||||||
| Devine, 2005 [ | - (Australia) | Women >70 y | 1077 | 75(3) | ACCV semi-quantitative FFQ | <0.84, 0.84–1.6, >1.6 (tertiles) | 1 | Hip BMD | Protein T3 vs T1: |
| FN BMD | NR, higher p<0.05 | ||||||||
| Fung, 2017 [ | Nurses' Health Study & Health Professionals Follow-Up Study (US) | Men ≥50 y and post-menopausal women | 74,443 women; 35,439 men | Whole sample ≥50 y; stratification: | Semi-quantitative FFQ | Women 14.3, 18.6, 24.4% of EI; men 14.2, 18.3, 23.4% of EI (whole sample). | 32 | Hip fracture | Protein Q5 vs Q1: |
| Hannan, 2000 [ | Framingham Osteoporosis Study (US) | Men and women | 855/615 | 75(4.4), 68–91 | Willett semi-quantitative FFQ | 0.21–0.71; 0.72–0.96; 0.97–1.23; 1.24–2.78 (quartiles) | 4 | FN BMD | Protein Q4 vs Q1: |
| LS BMD | Mean − 1.11(1.10)% vs −3.72(0.97)% p<0.05 | ||||||||
| Isanejad, 2017 [ | Osteoporosis Risk Factor and Fracture Prevention Study (Finland) | Women ≥65 y | 750/544 | 68.1(1.9), 65–72 | 3 d food records | 0.79, 0.90, 0.96, 1.18 (quartiles) | 3 | TB BMC | Per unit increase in energy-adjusted protein intake: |
| TB BMD | B 0.04 SE 0.01 p 0.507 | ||||||||
| FN BMD | B -0.01 SE 0.01 p 0.918 | ||||||||
| LS BMD | B -0.31 SE 0.01 p 0.001 | ||||||||
| Langsetmo, 2017 [ | Osteoporotic Fractures in Men Study (US) | Men ≥65 y | 5994/5875 | 73.6(5.9) | Modified Block FFQ | 0.67, 0.75, 0.83, 0.93 (quartiles) | 10.5–11.2 | Hip BMD | Per SD increase in protein intake (2.9% of EI): |
| Spine fracture | HR 1.06 (0.92, 1.22) p 0.45 | ||||||||
| Hip fracture | HR 0.84 (0.73, 0.95) p 0.01 | ||||||||
| Meng, 2009 [ | - (Australia) | Women 70–85 y | 1500/862 | 74.9(2.6) | ACCV quantitative FFQ | <0.84, 0.84–1.6, >1.6 (tertiles) | 5 | TB BMC | Protein T3 vs T1: |
| Misra, 2011 [ | Framingham Osteoporosis Study (US) | Men and women ≥68 y | 976/946 | No fracture: 75(5.0); fracture: 76(5.2) | Willett semi-quantitative FFQ | 46.5, 59.6, 67.7, 82.7 g/d (quartiles); | 11.6 (median) | Hip fracture | Protein Q2–4 vs Q1: |
| Rapuri, 2003 [ | Sites Testing Osteoporosis Prevention/ Intervention (US) | Women 65–77 y | 489/92 | 71.3(0.8), 72.2(0.8), 70.1(0.8), 69.9(0.8) (quartiles) | 7 d food diaries | 0.95, 0.94, 0.98, 0.99 g/kg bw/d; | 3 | TB BMD | Protein Q4 vs Q1: |
| Hip BMD | NR, no difference ns | ||||||||
| FN BMD | NR, no difference ns | ||||||||
| Spine BMD | NR, no difference ns | ||||||||
| Osteocalcin | Mean − 6.5(7.6)% vs −5.8(7.6)% p 0.042 | ||||||||
| N-telopeptide | Mean 12.1(11.2)% vs 10.4(11.0)% p 0.226 |
Note. BMC = bone mineral content; BMD = bone mineral density; EI = energy intake; FFQ = Food Frequency Questionnaire; FN = femoral neck; HR = hazard ratio; TB = total body; LS = lumbar spine; NR = not reported; ns = not significant; RR = risk ratio; SD = standard deviation; SE = standard error; US = United States.
Unit is g/kg bw/d, unless stated otherwise. Values presented as mean or range.
Values presented as mean(SE), mean (95% CI) or RR/HR (95% CI). BMD in g/cm2.
Summary table of the intervention study included in the analysis.
| First author, year [ref] | RCT name (country) | Participants | N baseline/ analysed | Baseline mean age(SD) | Protein source | Control diet intake | High protein intake | Study length (y) | Relevant outcomes | Effect sizes |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhu, 2011 [ | - (Australia) | Healthy ambulant post-menopausal women 70–80 y | 219/196 (after 1y) /179 (after 2y) | Protein: 74.2(2.8); placebo: 74.3(2.6) | Skim milk + whey protein isolate | 2.1 g (skim milk); after 2y: 1.1 g/kg bw/d | 30 g (skim milk + whey protein isolate); after 2y: 1.4 g/kg bw/d | 2 | Hip BMD | Mean change(SD) protein vs placebo (mg/cm2): |
| FN BMD | After 1y: −5.7(22) vs −2.6(24) p 0.34 |
Note. BMD = Bone Mineral Density; NR = Not Reported; ns = not significant; RCT = Randomized Controlled Trial; SD = Standard Deviation.
Newcastle - Ottawa quality assessment scale for selected cohort studies.
| First author, year [ref] | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of the exposure | Outcome of interest absent at baseline | Control for important confounders | Outcome assessment | Adequate follow-up duration | Completeness of cohort follow-up | Total points out of 9 | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|---|
| Beasley, 2014 [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 | Low |
| Cauley, 2016 [ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 | Low |
| Chan, 2011 [ | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | Some concerns |
| Dawson-Hughes, 2002 [ | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 6 | Low |
| Devine, 2005 [ | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 4 | Some concerns |
| Fung, 2017 [ | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 6 | Some concerns |
| Hannan, 2000 [ | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 5 | Some concerns |
| Isanejad, 2017 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | Low |
| Langsetmo, 2017 [ | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 | Low |
| Meng, 2009 [ | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 4 | High |
| Misra, 2011 [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | Low |
| Rapuri, 2003 [ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 6 | Some concerns |
Note. A study can be awarded a maximum of one point for each numbered item within the selection and outcome categories. A maximum of two points can be given for comparability.
Risk of bias in the selected intervention study using Cochrane Collaboration's tool.
| Author | Risk of selection bias | Risk of performance bias | Risk of attrition bias | Risk of detection bias | Risk of reporting bias | Overall risk of bias | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Random sequence allocation | Allocation concealment | Baseline differences | Total | Blinding of participants | Blinding of personnel | Appropriate analysis | Total | Complete outcome data | Missing outcome data | Total | Inappropriate outcome assessment | Outcome assessment group differences | Blinding | Total | Analysis as pre-specified | Selection on multiple outcome measurements | Selection on multiple analyses | Total | ||
| Zhu | L | L | L | Low | L | L | L | Low | PH | PL | Some concerns | L | L | L | Low | NI | L | NI | Some concerns | Low to some concerns |
Note. H = high; L = low; NI = no information; PH = probably high; PL = probably low.
Quality of evidence per outcome of interest from selected studies.
| Outcome | Number of cohort studies | Number of RCTs | Risk of bias | Imprecision | Consistency | Number of moderate quality studies | Overall quality rating |
|---|---|---|---|---|---|---|---|
| BMC - total body | 2 | 0 | Some concerns | Some concerns | 1 p, 1 ns | 0 | Very low |
| BMD | |||||||
| Total body | 4 | 0 | Low | Low | 1 p, 3 ns | 1 | Low |
| Total hip | 5 | 1 | Some concerns | Low | 2 p, 3 ns | 1 | Low |
| Femoral neck | 6 | 1 | Some concerns | Low | 3 p, 3 ns | 1 | Low |
| Lumbar spine | 4 | 0 | Some concerns | Low | 1 p, 1 n, 2 ns | 1 | Low |
| Bone turnover markers | |||||||
| Osteocalcin | 2 | 0 | Some concerns | Some concerns | 2 ns | 0 | Very low |
| N-telopeptide | 2 | 0 | Some concerns | Some concerns | 2 ns | 0 | Very low |
| Fracture | |||||||
| Total | 1 | 0 | Low | Low | 1 ns | 0 | Very low |
| Spine | 1 | 0 | Low | Low | 1 ns | 1 | Very low |
| Hip | 5 | 0 | Low | Low | 4 p, 1 ns | 2 | Low |
Note. According to the GRADE approach, evidence was graded as ‘High’, ‘Moderate’, ‘Low’, or ‘Very Low’ depending on several criteria. Risk of bias is a combined judgement from risk of bias in the individual studies. Indirectness was rated low for all outcomes. BMC = Bone Mineral Content; BMD = Bone Mineral Density; n = negative; ns = not significant; p = positive; RCT = Randomized Controlled Trial.
Fig. 2Effect of protein intake on hip fractures. Fixed-effect pooled hazard ratio (HR) analysis was used. Grey boxes represent the point estimates with the size of the box representing the weight of the study. Horizontal lines depict the length of the 95% CI. The diamond represents the pooled effect estimate.
* No exact sample size can be stated; the hazard ratio is the estimate of the effect at specific age levels (65 and 75 y) selected from a continuous distribution. Total sample size was 144,580 persons.